Message Font: Serif | Sans-Serif
No. of Recommendations: 0
Kathy, these approaches may be very efficacious. Being patient specific, they may be very costly and present bottlenecks in production that a less individual approach may avoid. You may want to look at Cell Genesys in addition to the two companies you have mentioned. They are very well capitalized, still a ten percent owner of Abgenix, I believe, which they spun off some time ago and which is a testament to Cell Genesys' business and scientific acumen. My understanding is that Cell Genesys engineers the gene for granulocyte-macrophage colony stimulating factor (GMCSF) into tumor cells using two approaches, one patient specific, the other not. These provoke the patient's immune system to attack the tumor. They have a number of things in phase 2 clinical trials and plan to initiate a phase 3 trial mid-2003 for their GVAX prostate cancer vaccine. In addition, they have upwards of 200 gene therapy patents. Personally, I think this is one company with legs.
Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.